

# Bas Groot Koerkamp

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8099253/publications.pdf>

Version: 2024-02-01

316  
papers

15,617  
citations

17440

63  
h-index

24982

109  
g-index

324  
all docs

324  
docs citations

324  
times ranked

11712  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 557-588.	17.8	1,155
2	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology</i> , The, 2016, 17, 801-810.	10.7	719
3	Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1763-1773.	1.6	665
4	Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD). <i>Annals of Surgery</i> , 2019, 269, 2-9.	4.2	401
5	Laparoscopic versus open pancreatoduodenectomy for pancreatic or periampullary tumours (LEOPARD-2): a multicentre, patient-blinded, randomised controlled phase 2/3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 199-207.	8.1	393
6	Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. <i>British Journal of Surgery</i> , 2018, 105, 946-958.	0.3	384
7	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. <i>Gut</i> , 2020, 69, 7-17.	12.1	357
8	Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1220-1230.	1.6	274
9	Alternative Fistula Risk Score for Pancreatoduodenectomy (a-FRS). <i>Annals of Surgery</i> , 2019, 269, 937-943.	4.2	257
10	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2019, 111, 782-794.	6.3	223
11	International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. <i>JAMA Surgery</i> , 2018, 153, e183617.	4.3	213
12	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). <i>Annals of Surgery</i> , 2019, 269, 10-17.	4.2	211
13	Benchmarks in Pancreatic Surgery. <i>Annals of Surgery</i> , 2019, 270, 211-218.	4.2	202
14	Surgery for cholangiocarcinoma. <i>Liver International</i> , 2019, 39, 143-155.	3.9	192
15	The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels. <i>Annals of Surgery</i> , 2019, 270, 139-146.	4.2	179
16	Postoperative Mortality after Liver Resection for Perihilar Cholangiocarcinoma: Development of a Risk Score and Importance of Biliary Drainage of the Future Liver Remnant. <i>Journal of the American College of Surgeons</i> , 2016, 223, 321-331e1.	0.5	161
17	Early <i>versus</i> late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. <i>British Journal of Surgery</i> , 2018, 105, 848-856.	0.3	158
18	Resection Margin and Survival in 2368 Patients Undergoing Hepatic Resection for Metastatic Colorectal Cancer. <i>Annals of Surgery</i> , 2015, 262, 476-485.	4.2	156

#	ARTICLE	IF	CITATIONS
19	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2019, 154, e190571.	4.3	149
20	Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Caseâ€“Control Study. <i>Annals of Surgical Oncology</i> , 2016, 23, 1361-1370.	1.5	148
21	Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure?. <i>Surgery</i> , 2018, 163, 1238-1244.	1.9	147
22	Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent Resection. <i>Journal of the American College of Surgeons</i> , 2015, 221, 1041-1049.	0.5	143
23	Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. <i>Cancer</i> , 2016, 122, 758-765.	4.1	138
24	Textbook Outcome. <i>Annals of Surgery</i> , 2020, 271, 155-162.	4.2	137
25	Endoscopic versus percutaneous biliary drainage in patients with resectable perihilar cholangiocarcinoma: a multicentre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 681-690.	8.1	126
26	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. <i>Journal of Hepatology</i> , 2022, 76, 1109-1121.	3.7	119
27	Circulating Tumor Cells and Prognosis of Patients with Resectable Colorectal Liver Metastases or Widespread Metastatic Colorectal Cancer: A Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2013, 20, 2156-2165.	1.5	116
28	Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2020, 155, 823.	4.3	116
29	Intrahepatic cholangiocarcinoma: current perspectives. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1131-1142.	2.0	115
30	Outcomes After Minimally-invasive Versus Open Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2020, 271, 356-363.	4.2	113
31	Volumeâ€“outcome relationships in pancreatoduodenectomy for cancer. <i>Hpb</i> , 2016, 18, 317-324.	0.3	112
32	Perioperative Hepatic Arterial Infusion Pump Chemotherapy Is Associated With Longer Survival After Resection of Colorectal Liver Metastases: A Propensity Score Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 1938-1944.	1.6	112
33	High mortality after ALPPS for perihilar cholangiocarcinoma: case-control analysis including the first series from the international ALPPS registry. <i>Hpb</i> , 2017, 19, 381-387.	0.3	111
34	Minimally invasive versus open pancreatoduodenectomy (LEOPARD-2): study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 1.	1.6	107
35	Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. <i>Annals of Surgery</i> , 2021, 274, e1187-e1195.	4.2	105
36	Survival after resection of perihilar cholangiocarcinomaâ€“development and external validation of a prognostic nomogram. <i>Annals of Oncology</i> , 2015, 26, 1930-1935.	1.2	103

#	ARTICLE	IF	CITATIONS
37	Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. <i>Journal of the American College of Surgeons</i> , 2016, 223, 493-505e2.	0.5	101
38	Impact of a Nationwide Training Program in Minimally Invasive Distal Pancreatectomy (LAELAPS). <i>Annals of Surgery</i> , 2016, 264, 754-762.	4.2	99
39	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. <i>European Journal of Cancer</i> , 2020, 125, 83-93.	2.8	98
40	Nationwide prospective audit of pancreatic surgery: design, accuracy, and outcomes of the Dutch Pancreatic Cancer Audit. <i>Hpb</i> , 2017, 19, 919-926.	0.3	97
41	The systemic immune-inflammatory index is associated with an increased risk of incident cancer: A population-based cohort study. <i>International Journal of Cancer</i> , 2020, 146, 692-698.	5.1	95
42	Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. <i>BMC Cancer</i> , 2021, 21, 300.	2.6	95
43	Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 52-59.	1.7	92
44	Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 160, 140-149.	2.8	90
45	Postoperative Liver Failure Risk Score: Identifying Patients with Resectable Perihilar Cholangiocarcinoma Who Can Benefit from Portal Vein Embolization. <i>Journal of the American College of Surgeons</i> , 2017, 225, 387-394.	0.5	87
46	Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection. <i>Annals of Surgery</i> , 2017, 266, 693-701.	4.2	86
47	Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 115, 696-703.	1.7	85
48	Variation in hospital mortality after pancreatoduodenectomy is related to failure to rescue rather than major complications: a nationwide audit. <i>Hpb</i> , 2018, 20, 759-767.	0.3	85
49	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. <i>JAMA Oncology</i> , 2020, 6, 1733.	7.1	85
50	Long-term yield of pancreatic cancer surveillance in high-risk individuals. <i>Gut</i> , 2022, 71, 1152-1160.	12.1	84
51	Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules. <i>Journal of Hepatology</i> , 2019, 71, 753-762.	3.7	81
52	The neutrophil-to-lymphocyte ratio is associated with mortality in the general population: The Rotterdam Study. <i>European Journal of Epidemiology</i> , 2019, 34, 463-470.	5.7	81
53	Uncertainty and Patient Heterogeneity in Medical Decision Models. <i>Medical Decision Making</i> , 2010, 30, 194-205.	2.4	79
54	Outcomes in biliary malignancy. <i>Journal of Surgical Oncology</i> , 2014, 110, 585-591.	1.7	78

#	ARTICLE	IF	CITATIONS
55	The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 431-438.	1.5	76
56	Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis. <i>Hpb</i> , 2017, 19, 901-909.	0.3	74
57	Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. <i>British Journal of Surgery</i> , 2018, 105, 857-866.	0.3	74
58	Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 2549-2557.	1.5	74
59	Treatment and survival of resected and unresected distal cholangiocarcinoma: a nationwide study. <i>Acta Oncol<sup>3</sup>gica</i> , 2019, 58, 1048-1055.	1.8	74
60	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. <i>Hepatology</i> , 2021, 74, 1429-1444.	7.3	73
61	Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers. <i>Annals of Surgery</i> , 2021, 274, 780-788.	4.2	72
62	Limitations of Acceptability Curves for Presenting Uncertainty in Cost-Effectiveness Analysis. <i>Medical Decision Making</i> , 2007, 27, 101-111.	2.4	70
63	Outcomes after Resection of Intrahepatic Cholangiocarcinoma: External Validation and Comparison of Prognostic Models. <i>Journal of the American College of Surgeons</i> , 2015, 221, 452-461.	0.5	70
64	Association of the location of pancreatic ductal adenocarcinoma (head, body, tail) with tumor stage, treatment, and survival: a population-based analysis. <i>Acta Oncol<sup>3</sup>gica</i> , 2018, 57, 1655-1662.	1.8	70
65	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 41.	2.8	68
66	Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 719-727.	1.0	67
67	The risk of not receiving adjuvant chemotherapy after resection of pancreatic ductal adenocarcinoma: a nationwide analysis. <i>Hpb</i> , 2020, 22, 233-240.	0.3	66
68	Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1841-1850.	1.7	65
69	Diagnostic value of C-reactive protein to rule out infectious complications after major abdominal surgery: a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2015, 30, 861-873.	2.2	64
70	Robotic <i>versus</i> laparoscopic distal pancreatectomy: multicentre analysis. <i>British Journal of Surgery</i> , 2021, 108, 188-195.	0.3	64
71	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. <i>Cancers</i> , 2019, 11, 976.	3.7	63
72	Perihilar Cholangiocarcinoma: Number of Nodes Examined and Optimal Lymph Node Prognostic Scheme. <i>Journal of the American College of Surgeons</i> , 2016, 222, 750-759e2.	0.5	61

#	ARTICLE	IF	CITATIONS
73	Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. <i>Annals of Surgical Oncology</i> , 2020, 27, 3318-3327.	1.5	59
74	Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial. <i>Lancet, The</i> , 2022, 399, 1867-1875.	13.7	59
75	Impact of major vascular resection on outcomes and survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2017, 116, 133-139.	1.7	57
76	Outcomes of a Multicenter Training Program in Robotic Pancreatoduodenectomy (LAELAPS-3). <i>Annals of Surgery</i> , 2022, 276, e886-e895.	4.2	57
77	Prognostic Biomarkers in Patients with Resected Cholangiocarcinoma: A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2014, 21, 487-500.	1.5	55
78	Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. <i>Surgery</i> , 2019, 166, 983-990.	1.9	54
79	Identifying key parameters in cost-effectiveness analysis using value of information: a comparison of methods. <i>Health Economics (United Kingdom)</i> , 2006, 15, 383-392.	1.7	52
80	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. <i>Annals of Surgery</i> , 2020, 272, 731-737.	4.2	49
81	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2020, 31, 1035-1043.e2.	0.5	49
82	Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Perioperative Outcomes. <i>World Journal of Surgery</i> , 2018, 42, 2551-2560.	1.6	47
83	American Joint Committee on Cancer staging for resected perihilar cholangiocarcinoma: a comparison of the 6th and 7th editions. <i>Hpb</i> , 2014, 16, 1074-1082.	0.3	46
84	The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients: A multi-institutional analysis. <i>Journal of Surgical Oncology</i> , 2017, 115, 312-318.	1.7	46
85	A comparison of treatment and outcomes of perihilar cholangiocarcinoma between Eastern and Western centers. <i>Hpb</i> , 2019, 21, 345-351.	0.3	46
86	Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2311-2318.	1.5	46
87	The prognostic value of portal vein and hepatic artery involvement in patients with perihilar cholangiocarcinoma. <i>Hpb</i> , 2018, 20, 83-92.	0.3	45
88	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102258.	7.7	45
89	Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases. <i>Annals of Surgical Oncology</i> , 2015, 22, 1156-1163.	1.5	44
90	The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2888-2901.	1.5	44

#	ARTICLE	IF	CITATIONS
91	Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2959-2968.	1.5	43
92	Establishing and Coordinating a Nationwide Multidisciplinary Study Group: Lessons Learned by the Dutch Pancreatic Cancer Group. <i>Annals of Surgery</i> , 2020, 271, e102-e104.	4.2	43
93	The Combined Analysis of Uncertainty and Patient Heterogeneity in Medical Decision Models. <i>Medical Decision Making</i> , 2011, 31, 650-661.	2.4	42
94	Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 1085-1095.	1.7	42
95	Preoperative biliary drainage in perihilar cholangiocarcinoma: identifying patients who require percutaneous drainage after failed endoscopic drainage. <i>Endoscopy</i> , 2015, 47, 1124-1131.	1.8	41
96	Costs and quality of life in a randomized trial comparing minimally invasive and open distal pancreatectomy (LEOPARD trial). <i>British Journal of Surgery</i> , 2019, 106, 910-921.	0.3	41
97	Efficacy and feasibility of stereotactic radiotherapy after folfinirox in patients with locally advanced pancreatic cancer (LAPC-1 trial). <i>EClinicalMedicine</i> , 2019, 17, 100200.	7.1	41
98	A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 1110-1119.	1.5	41
99	Minimally invasive versus open distal pancreatectomy (LEOPARD): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 166.	1.6	40
100	Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients. <i>Journal of Surgical Oncology</i> , 2019, 120, 206-213.	1.7	39
101	Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 1582-1594.	2.8	38
102	The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. <i>Surgery</i> , 2018, 164, 411-418.	1.9	38
103	Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. <i>British Journal of Surgery</i> , 2019, 106, 342-354.	0.3	38
104	Impact of Complications After Pancreatoduodenectomy on Mortality, Organ Failure, Hospital Stay, and Readmission. <i>Annals of Surgery</i> , 2022, 275, e222-e228.	4.2	38
105	Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing cancer surgery of the alimentary tract. <i>PLoS ONE</i> , 2017, 12, e0186547.	2.5	38
106	Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. <i>Journal of the American College of Surgeons</i> , 2018, 226, 393-403.	0.5	37
107	The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. <i>Hpb</i> , 2020, 22, 1667-1674.	0.3	37
108	Transatlantic registries of pancreatic surgery in the United States of America, Germany, the Netherlands, and Sweden: Comparing design, variables, patients, treatment strategies, and outcomes. <i>Surgery</i> , 2021, 169, 396-402.	1.9	37

#	ARTICLE	IF	CITATIONS
109	Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model. <i>Annals of Surgical Oncology</i> , 2020, 27, 2516-2524.	1.5	36
110	Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial. <i>BMC Cancer</i> , 2019, 19, 327.	2.6	33
111	Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 21-29.	1.7	33
112	Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4016-4016.	1.6	33
113	Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. <i>Journal of Surgical Oncology</i> , 2018, 118, 422-430.	1.7	33
114	Value of Information Analysis Used to Determine the Necessity of Additional Research: MR Imaging in Acute Knee Trauma as an Example. <i>Radiology</i> , 2008, 246, 420-425.	7.3	32
115	Postoperative surveillance of pancreatic cancer patients. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1770-1777.	1.0	32
116	Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 2239-2246.	1.7	32
117	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. <i>Modern Pathology</i> , 2021, 34, 4-12.	5.5	32
118	Detection, Treatment, and Survival of Pancreatic Cancer Recurrence in the Netherlands. <i>Annals of Surgery</i> , 2022, 275, 769-775.	4.2	32
119	A Comparison of Prognostic Schemes for Perihilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1716-1724.	1.7	31
120	Resection of Perihilar Cholangiocarcinoma. <i>Surgical Clinics of North America</i> , 2016, 96, 247-267.	1.5	31
121	Impact of Morphological Status on Long-Term Outcome Among Patients Undergoing Liver Surgery for Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2017, 24, 2491-2501.	1.5	31
122	Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1888-1897.	1.7	31
123	Developing a robotic pancreas program: the Dutch experience. <i>Journal of Visualized Surgery</i> , 2017, 3, 106-106.	0.2	31
124	Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage II Pancreatic Cancer – More is Better? A Large International Population-based Cohort Study. <i>Annals of Surgery</i> , 2021, 274, e554-e563.	4.2	31
125	Low Skeletal Muscle Density Is Associated with Early Death in Patients with Perihilar Cholangiocarcinoma Regardless of Subsequent Treatment. <i>Digestive Surgery</i> , 2019, 36, 144-152.	1.2	31
126	Development and Validation of a Laboratory Risk Score (LabScore) to Predict Outcomes after Resection for Intrahepatic Cholangiocarcinoma. <i>Journal of the American College of Surgeons</i> , 2020, 230, 381-391e2.	0.5	31



#	ARTICLE	IF	CITATIONS
127	Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Liver Cancer</i> , 2019, 8, 255-270.	7.7	30
128	Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 1970-1978.	1.5	30
129	Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2018, 20, 956-965.	0.3	28
130	Nationwide treatment and outcomes of perihilar cholangiocarcinoma. <i>Liver International</i> , 2021, 41, 1945-1953.	3.9	28
131	Histopathological Growth Patterns and Survival After Resection of Colorectal Liver Metastasis: An External Validation Study. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab026.	2.9	28
132	Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. <i>Hpb</i> , 2017, 19, 735-740.	0.3	27
133	Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. <i>Surgery</i> , 2018, 163, 1114-1120.	1.9	27
134	New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. <i>Surgery</i> , 2018, 164, 6-16.	1.9	27
135	Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma?. <i>Annals of Surgical Oncology</i> , 2019, 26, 2242-2250.	1.5	27
136	Histopathological growth patterns as biomarker for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. <i>Clinical and Experimental Metastasis</i> , 2020, 37, 593-605.	3.3	27
137	Recreating Tumour Complexity in a Dish: Organoid Models to Study Liver Cancer Cells and their Extracellular Environment. <i>Cancers</i> , 2019, 11, 1706.	3.7	26
138	A novel online prognostic tool to predict long-term survival after liver resection for intrahepatic cholangiocarcinoma: The "metro-ticket" paradigm. <i>Journal of Surgical Oncology</i> , 2019, 120, 223-230.	1.7	26
139	Minimally invasive versus open distal pancreatectomy: an individual patient data meta-analysis of two randomized controlled trials. <i>Hpb</i> , 2021, 23, 323-330.	0.3	26
140	Failure to Rescue After Pancreatoduodenectomy. <i>Annals of Surgery</i> , 2021, 274, 459-466.	4.2	26
141	Surgical Complications in a Multicenter Randomized Trial Comparing Preoperative Chemoradiotherapy and Immediate Surgery in Patients With Resectable and Borderline Resectable Pancreatic Cancer (PREOPANC Trial). <i>Annals of Surgery</i> , 2022, 275, 979-984.	4.2	26
142	Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment. <i>European Journal of Cancer</i> , 2022, 168, 25-33.	2.8	25
143	Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2022, 157, 590.	4.3	25
144	Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. <i>Acta Oncologica</i> , 2018, 57, 807-812.	1.8	24

#	ARTICLE	IF	CITATIONS
145	Variation in pancreatoduodenectomy as delivered in two national audits. <i>British Journal of Surgery</i> , 2019, 106, 747-755.	0.3	24
146	Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1612-1618.	1.7	24
147	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. <i>Annals of Surgery</i> , 2021, 274, 721-728.	4.2	24
148	Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 483-494.	3.3	24
149	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. <i>Cancer Medicine</i> , 2018, 7, 4943-4951.	2.8	23
150	Histopathological growth patterns and positive margins after resection of colorectal liver metastases. <i>Hpb</i> , 2020, 22, 911-919.	0.3	23
151	Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 7719-7729.	1.5	23
152	Preoperative systemic chemotherapy alters the histopathological growth patterns of colorectal liver metastases. <i>Journal of Pathology: Clinical Research</i> , 2022, 8, 48-64.	3.0	23
153	Value of Information Analyses of Economic Randomized Controlled Trials: The Treatment of Intermittent Claudication. <i>Value in Health</i> , 2010, 13, 242-250.	0.3	22
154	Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1906-1911.	1.0	22
155	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. <i>Cancers</i> , 2019, 11, 93.	3.7	22
156	Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. <i>Trials</i> , 2021, 22, 608.	1.6	22
157	Organoids Derived from Neoadjuvant FOLFIRINOX Patients Recapitulate Therapy Resistance in Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 6602-6612.	7.0	22
158	Care after pancreatic resection according to an algorithm for early detection and minimally invasive management of pancreatic fistula versus current practice (PORSCH-trial): design and rationale of a nationwide stepped-wedge cluster-randomized trial. <i>Trials</i> , 2020, 21, 389.	1.6	21
159	Systematic review and meta-analysis of validated prognostic models for resected hepatocellular carcinoma patients. <i>European Journal of Surgical Oncology</i> , 2022, 48, 492-499.	1.0	21
160	Preoperative misdiagnosis of pancreatic and periampullary cancer in patients undergoing pancreatoduodenectomy: A multicentre retrospective cohort study. <i>European Journal of Surgical Oncology</i> , 2021, 47, 2525-2532.	1.0	21
161	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. <i>Journal of Surgical Oncology</i> , 2018, 118, 1021-1026.	1.7	20
162	International Validation of Reduced Major Morbidity After Minimally Invasive Distal Pancreatectomy Compared With Open Pancreatectomy. <i>Annals of Surgery</i> , 2021, 274, e966-e973.	4.2	20

#	ARTICLE	IF	CITATIONS
163	A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. <i>Annals of Surgical Oncology</i> , 2020, 27, 5224-5232.	1.5	20
164	Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1156-1163.	1.7	20
165	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. <i>Journal of the National Cancer Institute</i> , 2022, 114, 695-703.	6.3	20
166	Robot-assisted spleen preserving pancreatic surgery in MEN1 patients. <i>Journal of Surgical Oncology</i> , 2016, 114, 456-461.	1.7	19
167	Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands. <i>Annals of Surgical Oncology</i> , 2019, 26, 4599-4607.	1.5	19
168	Surgical training model and safe implementation of robotic pancreatoduodenectomy in Japan: a technical note. <i>World Journal of Surgical Oncology</i> , 2021, 19, 55.	1.9	19
169	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8297-8308.	1.5	19
170	Long-Term Quality of Life after Minimally Invasive vs Open Distal Pancreatectomy in the LEOPARD Randomized Trial. <i>Journal of the American College of Surgeons</i> , 2021, 233, 730-739e9.	0.5	19
171	Clinical impact of the updated international postoperative pancreatic fistula definition in distal pancreatectomy. <i>Hpb</i> , 2018, 20, 1044-1050.	0.3	18
172	Long-term outcomes of patients with intraductal growth sub-type of intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2018, 20, 1189-1197.	0.3	18
173	Robotic Pancreatoduodenectomy: Patient Selection, Volume Criteria, and Training Programs. <i>Scandinavian Journal of Surgery</i> , 2020, 109, 29-33.	2.6	18
174	Trends in Treatment and Survival of Gallbladder Cancer in the Netherlands; Identifying Gaps and Opportunities from a Nation-Wide Cohort. <i>Cancers</i> , 2020, 12, 918.	3.7	18
175	Primary and secondary liver failure after major liver resection for perihilar cholangiocarcinoma. <i>Surgery</i> , 2021, 170, 1024-1030.	1.9	18
176	Patterns of recurrence after resection of gallbladder cancer without routine extrahepatic bile duct resection. <i>Hpb</i> , 2014, 16, 635-640.	0.3	17
177	Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study. <i>World Journal of Surgery</i> , 2018, 42, 849-857.	1.6	17
178	Recurrence Patterns After Resection of Colorectal Liver Metastasis are Modified by Perioperative Systemic Chemotherapy. <i>World Journal of Surgery</i> , 2020, 44, 876-886.	1.6	17
179	Primary tumor location and the prognosis of patients after local treatment of colorectal liver metastases: a systematic review and meta-analysis. <i>Hpb</i> , 2020, 22, 351-357.	0.3	17
180	Genomic FHIIT analysis in RER+ and RER? adenocarcinomas of the pancreas. , 2000, 27, 239-243.		16

#	ARTICLE	IF	CITATIONS
181	The accuracy of pre-operative imaging in the management of hepatic cysts. <i>Hpb</i> , 2015, 17, 889-895.	0.3	16
182	The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 477-485.	1.7	16
183	Quality and performance of validated prognostic models for survival after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. <i>Hpb</i> , 2021, 23, 25-36.	0.3	16
184	Venous wedge and segment resection during pancreatoduodenectomy for pancreatic cancer: impact on short- and long-term outcomes in a nationwide cohort analysis. <i>British Journal of Surgery</i> , 2021, 109, 96-104.	0.3	16
185	The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. <i>Hpb</i> , 2021, 23, 1321-1331.	0.3	16
186	Completion pancreatectomy or a pancreas-preserving procedure during relaparotomy for pancreatic fistula after pancreatoduodenectomy: a multicentre cohort study and meta-analysis. <i>British Journal of Surgery</i> , 2021, 108, 1371-1379.	0.3	16
187	Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 783-791.e1.	4.9	16
188	Cost-effectiveness analysis for surgeons. <i>Surgery</i> , 2009, 145, 616-622.	1.9	15
189	Validation of the Mayo Clinic Staging System in Determining Prognoses of Patients With Perihilar Cholangiocarcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1930-1939.e3.	4.4	15
190	Conditional survival in patients with unresectable perihilar cholangiocarcinoma. <i>Hpb</i> , 2017, 19, 966-971.	0.3	15
191	A preoperative prognostic model to predict surgical success in patients with perihilar cholangiocarcinoma. <i>Journal of Surgical Oncology</i> , 2018, 118, 469-476.	1.7	15
192	Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study. <i>Annals of Surgical Oncology</i> , 2021, 28, 835-843.	1.5	15
193	The use and clinical outcome of total pancreatectomy in the United States, Germany, the Netherlands, and Sweden. <i>Surgery</i> , 2021, 170, 563-570.	1.9	15
194	Randomized clinical trial and meta-analysis of the impact of a fibrin sealant patch on pancreatic fistula after distal pancreatectomy: CPR trial. <i>BJS Open</i> , 2021, 5, .	1.7	15
195	Current evidence of nutritional therapy in pancreatoduodenectomy: Systematic review of randomized controlled trials. <i>Annals of Gastroenterological Surgery</i> , 2019, 3, 620-629.	2.4	14
196	International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 796-803.	1.0	14
197	Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102975.	4.4	14
198	Unsupervised Subtyping of Cholangiocarcinoma Using a Deep Clustering Convolutional Autoencoder. <i>Lecture Notes in Computer Science</i> , 2019, , 604-612.	1.3	14

#	ARTICLE	IF	CITATIONS
199	Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 5528-5538.	1.5	14
200	Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1084-1091.	1.0	13
201	Eligibility for Liver Transplantation in Patients with Perihilar Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2021, 28, 1483-1492.	1.5	13
202	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only. <i>Annals of Surgery</i> , 2021, 274, 729-735.	4.2	13
203	Prognostic impact of perineural invasion in intrahepatic cholangiocarcinoma: multicentre study. <i>British Journal of Surgery</i> , 2022, 109, 610-616.	0.3	13
204	Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1813-1820.	1.7	12
205	C-reactive protein is superior to white blood cell count for early detection of complications after pancreatoduodenectomy: a retrospective multicenter cohort study. <i>Hpb</i> , 2020, 22, 1504-1512.	0.3	12
206	Preoperative Risk Score to Predict Occult Metastatic or Locally Advanced Disease in Patients with Resectable Perihilar Cholangiocarcinoma on Imaging. <i>Journal of the American College of Surgeons</i> , 2018, 227, 238-246e2.	0.5	11
207	Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decision-making programme using decision tables. <i>United European Gastroenterology Journal</i> , 2020, 8, 865-877.	3.8	11
208	Recurrence After Liver Resection of Colorectal Liver Metastases: Repeat Resection or Ablation Followed by Hepatic Arterial Infusion Pump Chemotherapy. <i>Annals of Surgical Oncology</i> , 2021, 28, 808-816.	1.5	11
209	Surgical morbidity in the first year after resection for perihilar cholangiocarcinoma. <i>Hpb</i> , 2021, 23, 1607-1614.	0.3	11
210	Relationship Between Quality of Life and Survival in Patients With Pancreatic and Periampullary Cancer: A Multicenter Cohort Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1354-1363.	4.9	11
211	Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma. <i>International Journal of Cancer</i> , 2022, 150, 1654-1663.	5.1	11
212	Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 5988-5999.	1.5	11
213	Histological and Molecular Subclassification of Pancreatic and Nonpancreatic Periampullary Cancers: Implications for (Neo) Adjuvant Systemic Treatment. <i>Annals of Surgical Oncology</i> , 2015, 22, 2401-2407.	1.5	10
214	Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study. <i>BMJ Open</i> , 2018, 8, e020731.	1.9	10
215	Nationwide practice and outcomes of endoscopic biliary drainage in resectable pancreatic head and periampullary cancer. <i>Hpb</i> , 2021, 23, 270-278.	0.3	10
216	Proposed modification of the eighth edition of the AJCC staging system for intrahepatic cholangiocarcinoma. <i>Hpb</i> , 2021, 23, 1456-1466.	0.3	10

#	ARTICLE	IF	CITATIONS
217	Adjuvant intra-arterial chemotherapy for patients with resected colorectal liver metastases: a systematic review and meta-analysis. <i>Hpb</i> , 2022, 24, 299-308.	0.3	10
218	Age and prognosis in patients with pancreatic cancer: a population-based study. <i>Acta Oncologica</i> , 2022, 61, 286-293.	1.8	10
219	Impact of Positive Lymph Nodes and Resection Margin Status on the Overall Survival of Patients with Resected Perihilar Cholangiocarcinoma: The ENSCCA Registry. <i>Cancers</i> , 2022, 14, 2389.	3.7	10
220	Novel homozygous deletions of chromosomal band 18q22 in pancreatic adenocarcinoma identified by STS marker scanning. <i>Cancer</i> , 1999, 25, 370-375.		9
221	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. <i>Pancreatology</i> , 2020, 20, 1723-1731.	1.1	9
222	Treatment and Survival of Elderly Patients with Stage II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium. <i>Annals of Surgical Oncology</i> , 2020, 27, 5337-5346.	1.5	9
223	Disease-free interval and tumor functional status can be used to select patients for resection/ablation of liver metastases from adrenocortical carcinoma: insights from a multi-institutional study. <i>Hpb</i> , 2020, 22, 169-175.	0.3	9
224	Preoperative predictors for early and very early disease recurrence in patients undergoing resection of pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2022, 24, 535-546.	0.3	9
225	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10902.	4.1	9
226	Sex, Gender and Age Differences in Treatment Allocation and Survival of Patients With Metastatic Pancreatic Cancer: A Nationwide Study. <i>Frontiers in Oncology</i> , 2022, 12, 839779.	2.8	9
227	Actual 10-Year Survival after Resection of Perihilar Cholangiocarcinoma: What Factors Preclude a Chance for Cure?. <i>Cancers</i> , 2021, 13, 6260.	3.7	9
228	The Dutch Pancreas Biobank Within the Parelshoer Institute. <i>Pancreas</i> , 2018, 47, 495-501.	1.1	8
229	A preliminary prediction model for potentially guiding patient choices between breast conserving surgery and mastectomy in early breast cancer patients; a Dutch experience. <i>Quality of Life Research</i> , 2018, 27, 545-553.	3.1	8
230	The impact of hepatic arterial infusion pump chemotherapy on hepatic recurrences and survival in patients with resected colorectal liver metastases. <i>Hpb</i> , 2020, 22, 1271-1279.	0.3	8
231	Impact of nationwide centralization of oesophageal, gastric, and pancreatic surgery on travel distance and experienced burden in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2022, 48, 348-355.	1.0	8
232	Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110337.	3.2	8
233	Short- and Long-Term Outcomes of Pancreatic Cancer Resection in Elderly Patients: A Nationwide Analysis. <i>Annals of Surgical Oncology</i> , 2022, 29, 6031-6042.	1.5	8
234	Cytopathological Analysis of Cyst Fluid Enhances Diagnostic Accuracy of Mucinous Pancreatic Cystic Neoplasms. <i>Medicine (United States)</i> , 2015, 94, e988.	1.0	7

#	ARTICLE	IF	CITATIONS
235	Quantitative Imaging Features and Postoperative Hepatic Insufficiency: A Multi-Institutional Expanded Cohort. <i>Journal of the American College of Surgeons</i> , 2018, 226, 835-843.	0.5	7
236	Added Value of Body Fat Distribution in Predicting Clinically Significant Pancreatic Fistula in the a-FRS Following Pancreatoduodenectomy Currently Unclear. <i>Annals of Surgery</i> , 2019, 269, e2-e3.	4.2	7
237	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. <i>Familial Cancer</i> , 2020, 19, 247-258.	1.9	7
238	Should jaundice preclude resection in patients with gallbladder cancer? Results from a nation-wide cohort study. <i>Hpb</i> , 2020, 22, 1686-1694.	0.3	7
239	Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 4326-4334.	1.5	7
240	Discordance in prediction of prognosis among patients with intrahepatic cholangiocarcinoma: A preoperative vs postoperative perspective. <i>Journal of Surgical Oncology</i> , 2019, 120, 946-955.	1.7	6
241	Axial slicing versus bivalving in the pathological examination of pancreatoduodenectomy specimens (APOLLO): a multicentre randomized controlled trial. <i>Hpb</i> , 2021, 23, 1349-1359.	0.3	6
242	Stereotactic Body Radiation Therapy after Chemotherapy for Unresectable Perihilar Cholangiocarcinoma: The STRONG Trial, a Phase I Safety and Feasibility Study. <i>Cancers</i> , 2021, 13, 3991.	3.7	6
243	Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: a Multi-institutional, International Study of 1221 patients. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2756-2765.	1.7	5
244	Impact of time interval between multidisciplinary team meeting and intended pancreatoduodenectomy on oncological outcomes. <i>BJS Open</i> , 2020, 4, 884-892.	1.7	5
245	Microscopic resection margin status in pancreatic ductal adenocarcinoma – A nationwide analysis. <i>European Journal of Surgical Oncology</i> , 2021, 47, 708-716.	1.0	5
246	A population-based study on incidence, treatment, and survival in ampullary cancer in the Netherlands. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1742-1749.	1.0	5
247	Primary Sclerosing Cholangitis-Associated Cholangiocarcinoma Demonstrates High Intertumor and Intratumor Heterogeneity. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00410.	2.5	5
248	High Systemic Immune Inflammation Index Is Associated With Low Skeletal Muscle Quantity in Resectable Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 827755.	2.8	5
249	Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 1220-1231.	2.1	5
250	Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. <i>Journal of Oncology</i> , 2022, 2022, 1-9.	1.3	5
251	Robotic Total Pancreatectomy: A Novel Pancreatic Head-First Approach (with Video). <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1649-1650.	1.7	4
252	The value of serum amylase and drain fluid amylase to predict postoperative pancreatic fistula after pancreatoduodenectomy: a retrospective cohort study. <i>Langenbeck's Archives of Surgery</i> , 2021, 406, 2333-2341.	1.9	4

#	ARTICLE	IF	CITATIONS
253	Outcome of pancreatic anastomoses during pancreatoduodenectomy in two national audits. <i>Surgery</i> , 2021, 170, 1799-1806.	1.9	4
254	Resection of the Portal-Superior Mesenteric Vein in Pancreatic Cancer. <i>Pancreas</i> , 2021, 50, 1218-1229.	1.1	4
255	Development and external validation of a prediction model for overall survival after resection of distal cholangiocarcinoma. <i>British Journal of Cancer</i> , 2022, 126, 1280-1288.	6.4	4
256	Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB). <i>JAMA Oncology</i> , 2022, 8, 929.	7.1	4
257	PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma. <i>Cancers</i> , 2022, 14, 2190.	3.7	4
258	A National Survey on Peri-interventional Management of Percutaneous Transhepatic Biliary Drainage. <i>Surgical Laparoscopy, Endoscopy and Percutaneous Techniques</i> , 2017, 27, 253-256.	0.8	3
259	Surgery for perihilar cholangiocarcinoma. <i>British Journal of Surgery</i> , 2018, 105, 771-772.	0.3	3
260	Radial margin status should be determined in resected perihilar cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 557-559.	1.5	3
261	Pancreatic resection in the pediatric, adolescent and young adult population: nationwide analysis on complications. <i>Hpb</i> , 2021, 23, 1175-1184.	0.3	3
262	Severe Salmonella spp. or Campylobacter spp. Infection and the Risk of Biliary Tract Cancer: A Population-Based Study. <i>Cancers</i> , 2020, 12, 3348.	3.7	3
263	The yield of chest computed tomography in patients with locally advanced pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 450-456.	1.7	3
264	Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 3685-3694.	1.5	3
265	Laparoscopic versus open extended radical left pancreatectomy for pancreatic ductal adenocarcinoma: an international propensity-score matched study. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 6949-6959.	2.4	3
266	Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS4171-TPS4171.	1.6	3
267	Preoperative serum ADAM12 levels as a stromal marker for overall survival and benefit of adjuvant therapy in patients with resected pancreatic and periampullary cancer. <i>Hpb</i> , 2021, 23, 1886-1896.	0.3	3
268	Right versus left: Impact of primary location on survival and cure in patients undergoing hepatic resection for metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 664-664.	1.6	3
269	Micronutrient deficiencies and anaemia in patients after pancreatoduodenectomy. <i>British Journal of Surgery</i> , 2021, 108, e74-e75.	0.3	3
270	Sensitivity of CT, MRI, and EUS-FNA/B in the preoperative workup of histologically proven left-sided pancreatic lesions. <i>Pancreatology</i> , 2022, 22, 136-141.	1.1	3



#	ARTICLE	IF	CITATIONS
271	Endoscopic treatment of a refractory intrahepatic bile leak by transpapillary placement of coils into a peripheral bile duct. <i>Gastrointestinal Endoscopy</i> , 2016, 84, 189-190.	1.0	2
272	Histopathological growth patterns as a guide for adjuvant systemic chemotherapy in patients with resected colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2019, 45, e10.	1.0	2
273	Outcome after resection for perihilar cholangiocarcinoma in patients with primary sclerosing cholangitis: an international multicentre study. <i>Hpb</i> , 2021, 23, 1751-1758.	0.3	2
274	Neoadjuvant FOLFIRINOX in patients with (borderline) resectable pancreatic cancer: A systematic review and patient-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16207-e16207.	1.6	2
275	The prognostic value of hepatic arterial and portal venous involvement in patients with perihilar cholangiocarcinoma. <i>Hpb</i> , 2017, 19, S47.	0.3	1
276	Robotic Total Pancreatectomy: A Narrative Review. <i>In Vivo</i> , 2021, 35, 1907-1911.	1.3	1
277	ASO Visual Abstract: Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer – A Systematic Review and Meta-analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 485-487.	1.5	1
278	C-reactive protein is superior to white blood cell count for early prediction of major complications after pancreatoduodenectomy. <i>Hpb</i> , 2020, 22, S422.	0.3	1
279	Significance of examined lymph node number in accurate staging and long-term survival in resected stage I-II pancreatic cancer: More is better? A large international population-based cohort study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 6503-6503.	1.6	1
280	Early Detection and Minimally Invasive Management of Complications Reduces Mortality after Pancreatic Resection: The Nationwide PORSCH Trial. <i>Hpb</i> , 2021, 23, S672.	0.3	1
281	Reply to W. Attaallah, A. Jain et al, and P. Mroczkowski et al. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	1
282	Timing of onset of systemic treatment in asymptomatic patients with metastatic pancreatic cancer: An international expert survey and case-vignette study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e16256-e16256.	1.6	1
283	Role of Circulating Tumor Cells in Metastatic Colorectal Cancer: Clinical Challenges and Opportunities. <i>Current Colorectal Cancer Reports</i> , 2012, 8, 186-191.	0.5	0
284	1936 A treatment threshold for decision making in breast cancer surgery for optimal quality of life. <i>European Journal of Cancer</i> , 2015, 51, S310-S311.	2.8	0
285	891 Coil Yourself out of Trouble - an Unusual Solution for an Unusual Problem. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB178.	1.0	0
286	Gastric Outlet Obstruction. <i>JAMA Surgery</i> , 2016, 151, 577.	4.3	0
287	Intrapancreatic Accessory Spleen Mimicking Pancreatic neoplasm. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 2104-2105.	1.7	0
288	Sarcopenia is associated with increased hospital expenditure in patients undergoing major cancer surgery of the alimentary tract. <i>Journal of Hepatology</i> , 2017, 66, S185.	3.7	0

#	ARTICLE	IF	CITATIONS
289	The prognostic value of hepatic artery and portal vein involvement in patients with perihilar cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 66, S447.	3.7	0
290	Conditional probability of long-term survival in patients with locally advanced and metastatic hilar cholangiocarcinoma. <i>Journal of Hepatology</i> , 2017, 66, S446-S447.	3.7	0
291	Lymph Node Staging in Patients Undergoing Hepatectomy for Intrahepatic Cholangiocarcinoma: An International Multicentric Analysis. <i>Gastroenterology</i> , 2017, 152, S1223.	1.3	0
292	Sarcopenia is associated with hospital expenditure in patients undergoing cancer surgery of the alimentary tract. <i>Hpb</i> , 2017, 19, S46-S47.	0.3	0
293	Low skeletal muscle density is associated with early death in patients with suspected perihilar cholangiocarcinoma. <i>Hpb</i> , 2017, 19, S34-S35.	0.3	0
294	Quantitative Imaging Features of Preoperative Computed Tomography Images Predict Post-Hepatectomy Liver Insufficiency: A Multi-Institutional Expansion Cohort. <i>Journal of the American College of Surgeons</i> , 2017, 225, S137.	0.5	0
295	Reply to H. Zhang et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 3266-3267.	1.6	0
296	Sarcopenia is not a predictor of survival or sorafenib toxicity in advanced hepatocellular carcinoma: A Dutch multicenter study. <i>Journal of Hepatology</i> , 2018, 68, S434.	3.7	0
297	Characteristics of postoperative pancreatic fistula on CT scan: A multicenter cohort study. <i>Pancreatology</i> , 2018, 18, S5-S6.	1.1	0
298	Patient-reported burden of intensified surveillance and surgery in high-risk individuals under pancreatic cancer surveillance. <i>Pancreatology</i> , 2019, 19, S31.	1.1	0
299	PO-0791 Neoadjuvant treatment potentially improves outcome in resectable pancreatic cancer: metaanalysis. <i>Radiotherapy and Oncology</i> , 2019, 133, S408-S409.	0.6	0
300	Response to the Comment on "Prediction of Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Resection: Validation of a Clinical Risk Score in Aninternational Cohort": <i>Annals of Surgery</i> , 2019, 269, e34-e35.	4.2	0
301	Screening for colorectal cancer after pancreatoduodenectomy for ampullary cancer. <i>European Journal of Surgical Oncology</i> , 2020, 46, 534-538.	1.0	0
302	ASO Visual Abstract: Surgery for Bismuth's "Corlette Type IV Perihilar Cholangiocarcinoma" Results from a Western Multicenter Collaborative Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 460-461.	1.5	0
303	771 IMPACT OF NATIONWIDE CENTRALIZATION OF ESOPHAGEAL, GASTRIC, AND PANCREATIC SURGERY ON TRAVEL DISTANCE AND EXPERIENCED BURDEN IN THE NETHERLANDS. <i>Ecological Management and Restoration</i> , 2021, 34, .	0.4	0
304	1473P Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort. <i>Annals of Oncology</i> , 2021, 32, S1089.	1.2	0
305	Endoscopic ultrasonography as additional preoperative workup is valuable in half of the patients with a pancreatic body or tail lesion. <i>Hpb</i> , 2021, , .	0.3	0
306	Primary and secondary liver failure after major liver resection for perihilar cholangiocarcinoma. <i>Hpb</i> , 2021, 23, S821-S822.	0.3	0

#	ARTICLE	IF	CITATIONS
307	A Colon Resection and Pump Implantation in the Same Surgical Procedure: Is it Safe?. Annals of Surgical Oncology, 2022, 29, 2754.	1.5	0
308	ASO Visual Abstract: Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2022, , 1.	1.5	0
309	ASO Visual Abstract: Tumor Necrosis Impacts the Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
310	ASO Author Reflections: Usage of Hepatic Arterial Infusion Pump Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2022, , 1.	1.5	0
311	ASO Visual Abstract: Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic Cancer. Annals of Surgical Oncology, 2022, , .	1.5	0
312	IMPACT OF ENDOSCOPIC ULTRASOUND EVALUATION WITH FINE-NEEDLE ASPIRATION OR FINE-NEEDLE BIOPSY IN RESECTABLE PERIHILAR CHOLANGIOCARCINOMA. Endoscopy, 2022, 54, .	1.8	0
313	A PROPENSITY MATCHED RETROSPECTIVE STUDY ON PREOPERATIVE BILIARY DRAINAGE IN PATIENTS WITH RESECTABLE PERIHILAR CHOLANGIOCARCINOMA: METAL BEATS PLASTIC STENTS?. Endoscopy, 2022, 54, .	1.8	0
314	INCIDENCE OF PANCREATIC CANCER WITHIN PANCREATIC CYSTIC NEOPLASM: 6-YEAR RESULTS FROM A NATIONWIDE PATHOLOGY DATABASE. Endoscopy, 2022, 54, .	1.8	0
315	ASO Visual Abstract: Short- and Long-Term Outcomes of Pancreatic Cancer Resection for Elderly Patients: A Nationwide Analysis. Annals of Surgical Oncology, 2022, , 1.	1.5	0
316	Robotic distal pancreatectomy, a novel standard of care? First benchmark values for surgical outcomes from 14 international expert centers. British Journal of Surgery, 2022, 109, .	0.3	0